Irreversible electroporation

Scandinavian ChemoTech Obtains Two Patent Approvals for the key Features of the Technical Platform Tumour Specific Electroporation

Retrieved on: 
Thursday, October 10, 2019
Branches of biology, Medicine, Biology, Biotechnology, Electroporation, Gene delivery, Microbiology, Molecular biology, Irreversible electroporation, Ire, Patent

STOCKHOLM, Oct. 10, 2019 /PRNewswire/ -- Scandinavian ChemoTech (ChemoTech) has today announced that the company has received the final notice from the Swedish patent Authorities (PRV) for two of its patent applications.

Key Points: 
  • STOCKHOLM, Oct. 10, 2019 /PRNewswire/ -- Scandinavian ChemoTech (ChemoTech) has today announced that the company has received the final notice from the Swedish patent Authorities (PRV) for two of its patent applications.
  • More specifically, the two patents involve many different unique technical solutions which are very critical for the innovation of the Tumour Specific Electroporation.
  • One of the most important features that now has received a patent protection, is the unique dynamic features that protects the treated tissue from Irreversible Electroporation that can result in an unwanted ablation.
  • Kommersiella rttigheter fr dessa patent tillhr: Scandinavian ChemoTech AB
    For more info please contact:

Desert Medical Imaging Doctors Presented Interim Clinical Study Results of MR-guided FLA Treatment of MR-visible Prostate Cancer at AdMeTech 4th Global Summit

Retrieved on: 
Tuesday, October 8, 2019
Medicine, RTT, Clinical medicine, Cancer, Histopathology, Prostate cancer, Laser, Ablation, Magnetic resonance imaging, Management of prostate cancer, Irreversible electroporation

of Desert Medical Imaging in Palm Springs, CA presented a poster at the AdMeTech 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer in Boston October 3-5, 2019.

Key Points: 
  • of Desert Medical Imaging in Palm Springs, CA presented a poster at the AdMeTech 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer in Boston October 3-5, 2019.
  • The poster describes nine year interim results from a clinical study regarding MR-guided Focal Laser Ablation treatment of low-intermediate-risk localized prostate cancer (NCT#02243033).
  • Some of the treatments in the clinical study have been performed using the TRANBERG laser applicator non-cooled, optimized for high-precision thermal ablation treatment.
  • Title: TRANSRECTALLY DELIVERED, OUTPATIENT MRI-GUIDED LASER FOCAL THERAPY OF PROSTATE CANCER: NINE YEAR INTERIM RESULTS( Click to view full poster and results ).

Desert Medical Imaging Doctors Presented Interim Clinical Study Results of MR-guided FLA Treatment of MR-visible Prostate Cancer at AdMeTech 4th Global Summit

Retrieved on: 
Tuesday, October 8, 2019
Medicine, RTT, Clinical medicine, Cancer, Histopathology, Prostate cancer, Laser, Ablation, Magnetic resonance imaging, Management of prostate cancer, Irreversible electroporation

of Desert Medical Imaging in Palm Springs, CA presented a poster at the AdMeTech 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer in Boston October 3-5, 2019.

Key Points: 
  • of Desert Medical Imaging in Palm Springs, CA presented a poster at the AdMeTech 4th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer in Boston October 3-5, 2019.
  • The poster describes nine year interim results from a clinical study regarding MR-guided Focal Laser Ablation treatment of low-intermediate-risk localized prostate cancer (NCT#02243033).
  • Some of the treatments in the clinical study have been performed using the TRANBERG laser applicator non-cooled, optimized for high-precision thermal ablation treatment.
  • Title: TRANSRECTALLY DELIVERED, OUTPATIENT MRI-GUIDED LASER FOCAL THERAPY OF PROSTATE CANCER: NINE YEAR INTERIM RESULTS ( Click to view full poster and results ).

Techsomed Secures $2.6M for Groundbreaking Real-time Predictive Imaging System for Thermal Ablation

Retrieved on: 
Wednesday, May 29, 2019
Medicine, Medical specialties, Interventional radiology, Clinical medicine, Plasma physics, Surgical oncology, Ablation, Medical physics, Oncology, Irreversible electroporation, Microwave ablation

The system transforms thermal ablation therapies from guesswork into precise, real-time, feedback-dependent treatments that minimize healthy tissue damage and maximize target tissue ablation, resulting in higher efficacy and lower recurrence rates.

Key Points: 
  • The system transforms thermal ablation therapies from guesswork into precise, real-time, feedback-dependent treatments that minimize healthy tissue damage and maximize target tissue ablation, resulting in higher efficacy and lower recurrence rates.
  • We believe that overcoming surgical limitations through real-time predictive imaging will become the new standard of care, making thermal ablation safer and more effective."
  • Says Techsomed founder and CEO Yossi Abu: "Techsomed's BioTrace system was designed to empower surgeons to fully realize the potential in thermal ablation therapies by reducing potential complications.
  • About Techsomed: Techsomed, a privately-held biotech company with headquarters in Israel, develops ultrasound-based real-time monitoring systems for thermal ablation procedures.

AngioDynamics Receives FDA Approval to Initiate Pilot Study for the Use of NanoKnife® to Treat Prostate Cancer

Retrieved on: 
Wednesday, May 22, 2019
Surgery, Health, Biotechnology, Clinical trials, Medical devices, Oncology, FDA, Branches of biology, Medicine, Biology, Medical physics, RTT, Interventional radiology, Irreversible electroporation, Medical technology, Surgical oncology, Prostate cancer, Electroporation, Nanoknife

The pilot study is intended to inform the design of a pivotal clinical study in the United States to support the approval of a future Premarket Approval Application (PMA).

Key Points: 
  • The pilot study is intended to inform the design of a pivotal clinical study in the United States to support the approval of a future Premarket Approval Application (PMA).
  • This pilot study represents the next step in our comprehensive approach to establish NanoKnife as a platform technology to treat numerous cancers and conditions.
  • Prostate cancer is the second leading cause of cancer death in American men1.
  • The NanoKnife System is a unique, minimally invasive technique that has been used to successfully treat focal prostate lesions through irreversible electroporation.

Tumor Ablation: Global Market Size, Share & Trends Analysis Report (2019) by Treatment, Technology and Application - Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 11, 2019
Surgery, Health, Medicine, RTT, Clinical medicine, Medical specialties, Interventional radiology, Cryoablation, Infectious causes of cancer, Ablation, Prostate cancer, Cancer, Breast cancer, Irreversible electroporation

The "Tumor Ablation Market Size, Share & Trends Analysis Report By Treatment (Surgical, Percutaneous), By Technology (Cryoablation, IRE, MWA, RFA), By Application (Liver, Lung, Breast, Prostate), And Segment Forecasts, 2019 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tumor Ablation Market Size, Share & Trends Analysis Report By Treatment (Surgical, Percutaneous), By Technology (Cryoablation, IRE, MWA, RFA), By Application (Liver, Lung, Breast, Prostate), And Segment Forecasts, 2019 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global tumor ablation market size is anticipated to reach USD 2.41 billion by 2026, according to this report.
  • The market is estimated to witness a healthy CAGR of 11.12% during the forecast period.
  • About 13% of the population suffers from cancer each year, as per the statistics by the World Health Organization (WHO).

The global tumor ablation market size is anticipated to reach USD 2.17 billion by 2025

Retrieved on: 
Tuesday, November 27, 2018
Medicine, Cancer, Hepatology, RTT, Health, Interventional radiology, Ablation, Hepatocellular carcinoma, Liver cancer, Lung cancer, Microwave ablation, Irreversible electroporation

LONDON, Nov. 26, 2018 /PRNewswire/ -- Tumor Ablation Market Size, Share & Trends Analysis Report By Treatment (Surgical, Percutaneous), By Application (Lung, Liver Cancer), By Technology (Radiofrequency, Microwave), And Segment Forecasts, 2018 - 2025

Key Points: 
  • LONDON, Nov. 26, 2018 /PRNewswire/ -- Tumor Ablation Market Size, Share & Trends Analysis Report By Treatment (Surgical, Percutaneous), By Application (Lung, Liver Cancer), By Technology (Radiofrequency, Microwave), And Segment Forecasts, 2018 - 2025
    The global tumor ablation market size is anticipated to reach USD 2.17 billion by 2025, according to a new report by Grand View Research, Inc.
  • Increasing cases of cancer across the globe is the key growth-driving factor for this market.
  • Active role of healthcare agencies and government in creating awareness about various cancer types is also expected to facilitate usage of tumor ablation therapy, thereby supporting market development.
  • Sedentary lifestyle and rising air pollution are contributing to growing prevalence of lung cancer
    North America led the overall tumor ablation market.